Drug intelligence / Profile preview

LXR-0151

Development stage: Phase 1
Lead developer: LXR Biotechnology
Modality: Small Molecules

Overview

LXR-0151 is a small molecule drug developed by LXR Biotechnology. It functions as an apoptosis inhibitor and was investigated primarily for immune system diseases, infectious diseases, and urogenital diseases. The drug's mechanism of action involves the inhibition of apoptosis pathways. Its development reached Phase 1 clinical trials in HIV-infected patients but has since been discontinued[1].

Brand names: Lexirin
Other names: LXR-0151LXR0151LXR 0151LexirinLXR015-1LXR-015-1LXR 015-1

Targets

NR1H3 (Liver X receptor beta)LXRB (Liver X receptor beta)

Beyond the preview

Go deeper on LXR-0151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXR-0151.

Explore the full profile